Santa Clara, Calif. -- Affymetrix, a Santa Clara-based developer of semiconductor technology for genetic analysis, said on Monday it has completed its $315 million acquisition of San Diego-based eBioscience, a developer of cell analysis products and technologies. The all-cash deal was first announced in early May. "This transaction is an important strategic step for Affymetrix," said Frank Witney, the president and CEO of Affymetrix. "Through the acquisition of eBio we now have a blue-chip portfolio of cell-based assays that diversify our business and open up important new avenues for growth." eBioscience will operate as a separate business unit within Affymetrix under its existing leadership team.